340B growth is real. But dollar-term growth doesn’t tell the full story. In the latest episode of Katy’s 340B Compass, Katy Lees examines why rising
Can your leadership team clearly explain where your 340B program has exposure? In this episode of Katy’s 340B Compass, Katy Lees examines 340B program oversight
Proposed changes to 340B reimbursement and new legislative frameworks are raising important questions for covered entities and safety-net hospitals. In this episode of Katy’s 340B
In today’s 340B environment, conversations about manufacturer-requested data often turn on a simple assumption: that the requested data is the same information covered entities already
In today’s 340B environment, how you communicate your program matters just as much as how you manage it. Organizations are increasingly expected to demonstrate not
Virtue 340B helps covered entities and pharmacy leaders move from reactive, vendor-dependent compliance to disciplined, transparent 340B program oversight. Build a compliant, defensible 340B program
The definition of a “patient” has long been a foundational element of 340B compliance, but that foundation is now being challenged. In AbbVie v. HHS,
There is a growing narrative that growth in the 340B program reflects misuse, abuse, or drift from its original intent. That narrative is gaining traction
At GCA340B, staying ahead of the compliance curve isn’t just a priority—it’s the promise we make to every Covered Entity we serve. Compliance and auditing are
Most 340B exposure comes from gradual operational drift, not bad intent. Virtue helps organizations detect and prevent it early. We help hospital leadership understand exposure,
